Therapeutic Effects of Serelaxin in Acute Heart Failure

摘要: Over the past few decades, research on peptide hormone, relaxin, has significantly improved our understanding of its biological actions under physiological and diseased conditions. This facilitated conducting clinical trials to explore use serelaxin (human recombinant relaxin). Acute heart failure (AHF) is a very difficult treat entity, with limited success so far in developing new drugs combat it. A recent phase-III RELAX-AHF trial using therapy given during hospitalization revealed acute (ameliorated dyspnea) chronic (improved 180-day survival) effects. Although these findings support substantial improvement by over currently available therapies for AHF, they also raise key questions stimulate hypotheses. To facilitate development as drug disease, joint efforts clinicians, scientists pharmacological industries are necessary study In this review, after providing brief summary pathophysiology we present working hypothesis mechanisms responsible observed efficacy AHF patients. The existing preclinical data supporting hypotheses summarized discussed. provides an excellent example bilateral nature translational research.  (Circ J 2014; 78: 542–552)